Combinaison d'un inhibiteur de la HMG-CoA reductase rosuvastatine avec un inhibiteur de la phosphodiesterase 4, tel que roflumilast, roflumilast-N-oxyde, pour le traitement de maladies pulmonaires inflammatoires
The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, a pharmaceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceutically acceptable salt of ROFLUMILAST-N-oxide, the HMG-CoA reductase inhibitor is ROSUVASTATIN or a pharmaceutically acceptable salt thereof.
